European Journal of Cardiovascular Medicine

Surgical site infections (SSIs) represent a significant burden on the healthcare system, affecting approximately 2-5% of surgeries, with even higher rates observed in complex surgical procedures[1]. These infections can lead to increased morbidity, extended hospital stays, and heightened healthcare costs. Prophylactic antibiotic regimens, administered before the incision, have been widely accepted as a crucial strategy in reducing the incidence of SSIs[2]. However, the effectiveness and optimal choice of these regimens, especially in complex surgeries, remain subjects of ongoing research and debate.

The concept of using prophylactic antibiotics to prevent SSIs was introduced in the 1960s, based on the premise that preventing bacterial colonization at the surgical site could significantly reduce postoperative infections[3]. Since then, numerous studies have demonstrated the efficacy of prophylactic antibiotics in various surgical procedures, leading to the development of guidelines for their use[4]. Despite these advances, the incidence of SSIs, particularly in complex surgeries involving multiple surgical fields or prolonged operative times, remains a challenge[5].

Complex surgeries, such as those involving the abdominal cavity, cardiovascular system, or orthopedic implants, are inherently at a higher risk for SSIs due to the duration of the procedure, the specific flora of the surgical site, and the potential for foreign body implantation[6]. Moreover, the emergence of antibiotic-resistant bacteria has further complicated the selection of appropriate prophylactic antibiotic regimens[7]. This has led to a growing need for evidence-based recommendations that can effectively guide the choice of prophylaxis in these high-risk procedures.

Recent studies have begun to address these challenges by evaluating the efficacy of different antibiotic regimens in complex surgeries. For instance, randomized controlled trials (RCTs) comparing single-dose versus extended prophylaxis have provided insights into the optimal duration of antibiotic coverage[8]. Similarly, the comparison of broad-spectrum versus targeted antibiotics has explored the balance between efficacy and the risk of developing antibiotic resistance[9].

This prospective randomized controlled trial aims to fill the gaps in current knowledge by systematically comparing the incidence of SSIs in patients undergoing complex surgeries, who are administered different prophylactic antibiotic regimens. By focusing on a high-risk population and incorporating modern microbiological techniques to identify causative pathogens, this study seeks to provide robust evidence that can guide clinical practice.

Given the complexity of this issue, it is imperative to consider factors such as the timing of antibiotic administration, the pharmacokinetics and pharmacodynamics of the chosen agents, and the specific challenges posed by the surgical site and the patient's comorbidities[10]. This trial is designed with these considerations in mind, ensuring that the findings will have practical implications for the prevention of SSIs in complex surgical procedures.

Aims and Objectives:

The primary aim of the study was to assess the effectiveness of different prophylactic antibiotic regimens in reducing the incidence of surgical site infections (SSIs) in patients undergoing complex surgeries. Specifically, the trial sought to compare the incidence rates of SSIs among groups receiving different antibiotic prophylaxis protocols. The objective included evaluating the safety profile of these regimens, identifying any adverse reactions, and analyzing the antibiotic resistance patterns among the pathogens isolated from SSIs. This comprehensive approach aimed to generate evidence-based recommendations for antibiotic prophylaxis in complex surgical procedures, thereby enhancing patient outcomes and minimizing the risk of SSIs.

The study was conducted at the District Hospital in Sheopur, starting from June 2023 and concluding in December 2023. This period allowed for the recruitment of participants, the conduct of the surgeries, and the postoperative follow-up necessary for the evaluation of SSIs according to the criteria set forth by the Centers for Disease Control and Prevention (CDC).

A total sample size of 100 patients was determined using a statistical power analysis, which accounted for an anticipated drop-out rate of 10%, ensuring that the study retained enough power to detect a significant difference between the prophylactic antibiotic regimens with a 90% confidence interval (CI) and a margin of error (ME) of 5%. The sample size calculation was based on previous literature and pilot studies that indicated the expected incidence rates of SSIs in complex surgeries with and without effective antibiotic prophylaxis.

Patients scheduled for complex surgeries, including but not limited to abdominal, cardiovascular, and orthopedic procedures, were screened for eligibility. The inclusion criteria were adults aged 18 years and above, scheduled for a complex surgical procedure that was expected to last more than two hours, and able to provide informed consent. Exclusion criteria included patients with a known allergy to the study antibiotics, those who had received systemic antibiotics within 48 hours before the surgery (to avoid confounding the assessment of prophylactic antibiotics), pregnant or breastfeeding women, and patients with immune-compromising conditions, which could independently affect the risk of SSIs.

Eligible patients were randomized into groups, each receiving a different prophylactic antibiotic regimen according to the study protocol. The randomization was performed using a computer-generated sequence to ensure the groups were comparable at baseline. The administration of antibiotics was timed according to the best practices, generally within one hour before the incision. The choice of antibiotics for each group was based on the current guidelines, spectrum of activity, and the anticipated flora of the specific surgical sites.

Group Allocations

The study was meticulously designed to compare the efficacy of two distinct prophylactic antibiotic regimens in preventing surgical site infections (SSIs) among patients undergoing complex surgeries. This prospective randomized controlled trial, conducted over a six-month period from June 2023 to December 2023 at a district hospital in Sheopur, involved a sample size of 100 participants. These participants were randomly assigned to one of two groups, Group A and Group B, each consisting of 50 patients. The allocation to groups was determined by a computer-generated randomization sequence to ensure unbiased distribution.

Group A (Broad-Spectrum Antibiotic Regimen): Participants in this group received a broad-spectrum antibiotic regimen as prophylaxis against SSIs. The choice of broad-spectrum antibiotics was based on their effectiveness against a wide range of bacteria, aiming to cover most potential pathogens that could cause infections post-surgery. This approach is typically recommended when the bacterial flora at the surgical site is diverse or when specific pathogen information is lacking.

Group B (Targeted Antibiotic Regimen): Conversely, participants in Group B were administered a targeted antibiotic regimen. This regimen was selected based on the most common pathogens known to cause SSIs in the type of surgery being performed. The targeted antibiotic therapy was chosen with the intention of minimizing the use of broad-spectrum antibiotics, thereby reducing the risk of developing antibiotic resistance.

The study employed a prospective, randomized controlled design. Data on SSIs were collected through direct examination of surgical sites, cultures of suspected infections, and review of medical records for six weeks post-surgery, the period during which most SSIs are known to manifest. Adverse reactions to antibiotics were monitored and recorded throughout the study period.

Data analysis involved comparing the incidence of SSIs between the different prophylaxis groups using chi-square tests for categorical variables and t-tests for continuous variables. Multivariable logistic regression was used to adjust for potential confounders, including the duration of surgery, type of surgery, and patient comorbidities. The level of antibiotic resistance among the pathogens isolated from SSIs was analyzed to identify any patterns related to the prophylactic regimens used.

In the prospective randomized controlled trial conducted to assess the impact of prophylactic antibiotic regimens on the incidence of surgical site infections (SSIs) in complex surgeries, a total of 100 participants were enrolled and equally divided into two groups based on the antibiotic regimen received. Group A was administered a broad-spectrum antibiotic regimen, while Group B received a targeted antibiotic approach.

The baseline characteristics of the participants, including age, gender, body mass index (BMI), and comorbid conditions such as diabetes and hypertension, were comparable between the two groups, with no significant differences observed (p > 0.05 for all comparisons). The mean age of participants in Group A was 55.4 ± 12.3 years, and in Group B, it was 56.1 ± 11.7 years. The distribution of male and female participants was also similar across both groups.

Surgical procedures varied among participants, with abdominal, cardiovascular, and orthopedic surgeries being the most common. The allocation of these procedures was evenly distributed between the two groups, ensuring a balanced representation of complex surgeries (p > 0.05).

The incidence of SSIs did not significantly differ between the two antibiotic regimen groups, with Group A experiencing a 16% incidence rate (8 out of 50) and Group B a 10% incidence rate (5 out of 50), resulting in a p-value of 0.45. This finding suggests that the type of prophylactic antibiotic regimen, broad-spectrum versus targeted, may not significantly influence the overall risk of SSIs in the context of complex surgeries.

Further analysis revealed a significant difference in the incidence of SSIs when comparing complex versus less complex surgeries, with complex surgeries exhibiting a higher SSI rate of 20% compared to 6% for less complex procedures (p = 0.03). This underscores the heightened risk associated with the complexity of the surgical procedure itself.

Multivariate analysis identified several risk factors significantly associated with an increased likelihood of SSIs. Age over 60 years and the presence of diabetes were significant predictors, with odds ratios of 2.3 (95% CI: 1.1-4.8, p = 0.03) and 3.5 (95% CI: 1.8-6.7, p < 0.001), respectively. Additionally, surgeries lasting longer than 3 hours were associated with a fourfold increase in the risk of SSIs (OR = 4.0, 95% CI: 2.1-7.6, p < 0.001), highlighting the impact of procedure duration on infection risk.

The study also investigated antibiotic resistance patterns among the identified pathogens. Resistance rates were slightly higher for Regimen A (broad-spectrum) compared to Regimen B (targeted), although these differences were not statistically significant (p > 0.05), suggesting a nuanced relationship between antibiotic regimen selection and pathogen resistance profiles.

Finally, the duration of hospital stay post-surgery was significantly longer for patients who developed SSIs, averaging 12.4 ± 4.2 days compared to 6.9 ± 2.1 days for those without infections (p < 0.001). This finding highlights the substantial impact of SSIs on patient recovery and hospital resource utilization.

In summary, this study provided valuable insights into the relationship between prophylactic antibiotic regimens and the incidence of SSIs in complex surgeries. While the choice of antibiotic regimen did not significantly affect SSI rates, the complexity of the surgery, the duration of the procedure, and certain patient-specific factors were identified as significant risk factors for developing SSIs. These results underscore the importance of personalized, risk-based approaches to prophylactic antibiotic use in complex surgical procedures.

Table 1: Characteristics of Study Participants at Baseline

Table 2: Distribution of Surgical Procedures Among Participants

Table 3: Prophylactic Antibiotic Regimens Administered

Table 4: Incidence of Surgical Site Infections (SSIs) by Antibiotic Regimen

Table 5: Comparison of SSI Incidence Between Complex and Less Complex Surgeries

Table 6: Multivariate Analysis of Risk Factors for SSIs

Table 7: Antibiotic Resistance Patterns of Identified Pathogens

Table 8: Duration of Hospital Stay Post-Surgery by Infection Status

Top of Form

The findings of this study contribute to the ongoing discourse on the optimization of prophylactic antibiotic regimens to minimize the incidence of surgical site infections (SSIs) in complex surgeries. Despite the lack of significant difference in SSI rates between broad-spectrum and targeted antibiotic prophylaxis groups, the research underscores the multifaceted nature of SSI risk factors, including surgical complexity, operation duration, patient age, and the presence of comorbidities such as diabetes.

The absence of a significant difference in SSI incidence between the two antibiotic regimen groups is consistent with previous research, suggesting that the effectiveness of prophylactic antibiotics may be less about the spectrum of activity and more about appropriate selection, timing, and dosage. Studies have highlighted the critical role of administering antibiotics within one hour before incision to maximize efficacy against potential pathogens encountered during surgery[11]. This practice is supported by guidelines from authorities such as the American Society of Health-System Pharmacists and the Infectious Diseases Society of America, which emphasize the importance of timing in prophylactic antibiotic administration[12].

The increased SSI risk associated with complex surgeries and extended operation times found in this study aligns with the literature, which has long recognized these factors as critical in SSI risk. Complex surgeries often involve longer exposure times to potential contaminants and more extensive tissue manipulation, both of which can contribute to infection risk[13]. Furthermore, the positive correlation between operation duration and SSI incidence has been well-documented, with each additional hour of surgery increasing the SSI risk[14].

Our findings regarding the heightened SSI risk in patients with diabetes and those over 60 years of age corroborate previous studies indicating that these patient populations are particularly vulnerable. The impaired immune response in older adults and individuals with diabetes can significantly impact wound healing and infection resistance, necessitating careful perioperative management[15].

The observed patterns of antibiotic resistance among the identified pathogens did not significantly influence the outcome of the prophylactic regimens used in this study. However, the global challenge of antibiotic resistance remains a pressing concern, highlighting the need for judicious use of antibiotics and the development of novel antimicrobial agents[16].

Lastly, the extended hospital stay for patients who developed SSIs emphasizes the substantial economic and clinical burdens of these infections. SSIs have been associated with increased healthcare costs, longer hospitalization, and higher rates of readmission[17]. Preventive strategies, including optimized antibiotic prophylaxis, are essential for reducing these burdens.

The present study evaluated the efficacy of prophylactic antibiotic regimens in reducing the incidence of surgical site infections (SSIs) in complex surgeries. Our findings suggest that the specific choice between broad-spectrum and targeted antibiotic regimens does not significantly impact the overall SSI rate among patients undergoing complex surgical procedures. The incidence rates of SSIs were 16% in the broad-spectrum group and 10% in the targeted antibiotic group, with no statistical significance (p=0.45) observed between them.

However, the study highlighted several critical factors associated with an increased risk of SSIs, including the complexity of the surgical procedure, patient age over 60 years, the presence of diabetes, and surgeries extending beyond 3 hours. These findings are in line with existing literature that emphasizes the role of surgical complexity and procedure duration as substantial risk factors for SSIs [11][12]. Furthermore, the study underlines the significant burden of SSIs on healthcare resources, as evidenced by the extended hospital stays for patients who developed infections post-surgery.

1. Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol. 1999 Apr;20(4):250-78.
2. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, Fish DN, Napolitano LM, Sawyer RG, Slain D, Steinberg JP, Weinstein RA. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013 Feb 1;70(3):195-283.
3. Burke JF. The effective period of preventive antibiotic action in experimental incisions and dermal lesions. Surgery. 1961 Jul;50:161-8.
4. Classen DC, Evans RS, Pestotnik SL, Horn SD, Menlove RL, Burke JP. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med. 1992 Feb 27;326(9):281-6.
5. Allegranzi B, Zayed B, Bischoff P, Kubilay NZ, de Jonge S, de Vries F, Gomes SM, Gans S, Wallert ED, Wu X, Boermeester MA, Dellinger EP, Egger M, Gastmeier P, Guirao X, Ren J, Pittet D, Solomkin JS. New WHO recommendations on intraoperative and postoperative measures for surgical site infection prevention: an evidence-based global perspective. Lancet Infect Dis. 2016 Dec;16(12):e288-e303.
6. Anderson DJ, Podgorny K, Berríos-Torres SI, Bratzler DW, Dellinger EP, Greene L, Nyquist AC, Saiman L, Yokoe DS, Maragakis LL, Kaye KS. Strategies to prevent surgical site infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014 May;35 Suppl2:S66-88.
7. Spellberg B, Guidos R, Gilbert D, Bradley J, Boucher HW, Scheld WM, Bartlett JG, Edwards J Jr. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008 Jan 15;46(2):155-64.
8. Wenzel RP, Nettleman MD, Jones RN, Pfaller MA. Antibiotic prevention of acute exacerbations of COPD. N Engl J Med. 1995 Oct 19;333(16):1075-9.
9. Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin-sulbactam/amoxicillin-clavulanate. Clin Infect Dis. 2004 Jan 15;38(1):17-24.
10. Owens CD, Stoessel K. Surgical site infections: epidemiology, microbiology and prevention. J Hosp Infect. 2008 Nov;70 Suppl 2:3-10.
11. Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, Fish DN, Napolitano LM, Sawyer RG, Slain D, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70(3):195-283.
12. Anderson DJ, Podgorny K, Berríos-Torres SI, Bratzler DW, Dellinger EP, Greene L, Nyquist AC, Saiman L, Yokoe DS, Maragakis LL, et al. Strategies to prevent surgical site infections in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35 Suppl2:S66-88.
13. Allegranzi B, Bagheri Nejad S, Combescure C, Graafmans W, Attar H, Donaldson L, Pittet D. Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis. Lancet. 2011;377(9761):228-241.
14. Owens CD, Stoessel K. Surgical site infections: epidemiology, microbiology and prevention. J Hosp Infect. 2008;70 Suppl 2:3-10.
15. Sorensen LT. Wound healing and infection in surgery: The clinical impact of smoking and smoking cessation: A systematic review and meta-analysis. Arch Surg. 2012;147(4):373-383.